First, payers and physicians have wanted strong evidence that dramatic lowering of LDL-c with a PCSK9 inhibitor actually reduces cardiovascular event rates. Unlike Praluent, Repatha has yet to demonstrate a risk in overall death. Then, there is the curious case of Esperion’s LDL-c lowering drug, bempedoic acid. Esperion has recently reported the first Phase 3 results with bempedoic acid and has shown that in combination with yet another LDL-c lowering drug, Merck’s Zetia, it lowers LDL-c by 28% more than Zetia alone. The exact same thing is happening now with the newest LDL-c lowering agents.

Source: Forbes March 12, 2018 12:37 UTC